Baker BROS. Advisors LP Buys 737,988 Shares of Generation Bio Co. (NASDAQ:GBIO)

Baker BROS. Advisors LP grew its stake in Generation Bio Co. (NASDAQ:GBIO) by 61.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,944,945 shares of the company’s stock after buying an additional 737,988 shares during the period. Baker BROS. Advisors LP owned 2.91% of Generation Bio worth $4,804,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in Generation Bio by 23.9% during the 2nd quarter. Acadian Asset Management LLC now owns 594,569 shares of the company’s stock valued at $1,675,000 after purchasing an additional 114,734 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after purchasing an additional 44,378 shares during the last quarter. American Century Companies Inc. increased its position in shares of Generation Bio by 199.3% during the second quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock worth $90,000 after buying an additional 21,167 shares during the period. Vanguard Group Inc. raised its stake in Generation Bio by 0.7% during the first quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock worth $10,462,000 after buying an additional 18,205 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Generation Bio in the third quarter valued at $42,000. 95.22% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on GBIO shares. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Generation Bio in a report on Wednesday, October 23rd. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, November 7th.

Generation Bio Stock Up 6.3 %

Generation Bio stock opened at $1.52 on Monday. The company has a market capitalization of $101.53 million, a PE ratio of -0.69 and a beta of 2.82. Generation Bio Co. has a 12-month low of $1.13 and a 12-month high of $4.65. The firm’s fifty day moving average is $2.12 and its 200 day moving average is $2.57.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.